Successful use of recombinant factor VIII devoid of von Willebrand factor during multiple teeth extractions in a patient with type 3 von Willebrand disease

Blood Coagulation and Fibrinolysis

Volumn 17, Issue 2, 2006, Pages 151-154

  Sakurai, Yoshihiko ^a   Shima, Midori ^a   Imai, Yuichirou ^a   Omura, Shoko ^a   Kirita, Tadaaki ^a   Yoshioka, Akira ^a  

^a NARA MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Factor VIII; Inhibitor; Type 3 von Willebrand disease

Indexed keywords

ALLOANTIBODY; BLOOD CLOTTING FACTOR 8 INHIBITOR; BLOOD CLOTTING FACTOR 8C; RECOMBINANT BLOOD CLOTTING FACTOR 8; VON WILLEBRAND FACTOR;

ADULT; ARTICLE; BLEEDING; BLOOD CLOTTING; BOLUS INJECTION; CASE REPORT; DENTAL CARIES; DRUG DOSE REGIMEN; HEMOSTASIS; HUMAN; MALE; PERIODONTITIS; PRIORITY JOURNAL; SUTURE REMOVAL; TOOTH EXTRACTION; VON WILLEBRAND DISEASE;

BLOOD LOSS, SURGICAL; DENTAL CARIES; FACTOR VIII; HUMANS; MALE; MIDDLE AGED; PERIODONTITIS; TOOTH EXTRACTION; VON WILLEBRAND DISEASE; VON WILLEBRAND FACTOR;

EID: 33646108338     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mbc.0000214711.19116.09     Document Type: Article

References (14)

1. Sadler JE. A revised classification of von Willebrand disease. For the Subcommittee on von Willebrand Factor of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost 1994; 71:520-525.
2. Mannucci PM. How I treat patients with von Willebrand disease. Blood 2001; 97:1915-1919.
3. Mannucci PM. Treatment of von Willebrand's Disease. N Engl J Med 2004; 351:683-694.
4. Ironside JW, Head MW. Variant Creutzfeldt-Jakob disease: risk of transmission by blood and blood products. Haemophilia 2004; 10 (Suppl 4):64-69.
5. Mannucci PM, Federici AB. Antibodies to von Willebrand factor in von Willebrand disease. In: Aledort LM, Hoyer LW, Reisner JM, White II CC, editors. Inhibitors to coagulation factor in the 1990s. New York: Plenum Press; 1995, pp. 87-92.
6. Mannucci PM, Tamaro G, Narchi G, Candotti G, Federici A, Altieri D, et al. Life-threatening reaction to factor VIII concentrate in a patient with severe von Willebrand disease and alloantibodies to von Willebrand factor. Eur J Haematol 1987; 39:467-470.
7. Bergamaschini L, Mannucci PM, Federici AB, Coppola R, Guzzoni S, Agostoni A. Posttransfusion anaphylactic reactions in a patient with severe von Willebrand disease: role of complement and alloantibodies to von Willebrand factor. J Lab Clin Med 1995; 125:348-355.
8. Boyer-Neumann C, Dreyfus M, Wolf M, Veyradier A, Meyer D. Multitherapeutic approach to manage delivery in an alloimmunized patient with type 3 von Willebrand disease. J Thromb Haemost 2003; 1:190-192.
9. Ciavarella N, Schiavoni M, Valenzano E, Mangini F, Inchingolo F. Use of recombinant factor Vila (NovoSeven) in the treatment of two patients with type III von Willebrand's disease and an inhibitor against von Willebrand factor. Haemostasis 1996; 26 (Suppl 1):150-154.
10. Grossmann RE, Geisen U, Schwender S, Keller F. Continuous infusion of recombinant factor Vila (NovoSeven) in the treatment of a patient with type III von Willebrand's disease and alloantibodies against von Willebrand factor. Thromb Haemost 2000; 83:633-634.
11. Tuddenham EG, Lane RS, Rotblat F, Johnson AJ, Snape TJ, Middleton S, et al. Response to infusions of polyelectrolyte fractionated human factor VIII concentrate in human haemophilia A and von Willebrand's disease. Br J Haematol 1982; 52:259-267.
12. Lethagen S, Berntorp E, Nilsson IM. Pharmacokinetics and hemostatic effect of different factor VIII/von Willebrand factor concentrates in von Willebrand's disease type III. Ann Hematol 1992; 65:253-259.
13. Morfini M, Mannucci PM, Tenconi PM, Longo G, Mazzucconi MG, Rodeghiero F, et al. Pharmacokinetics of monoclonally-purified and recombinant factor VIII in patients with severe von Willebrand disease. Thromb Haemost 1993; 70:270-272.
14. Stachnik JM, Gabay MP. Continuous infusion of coagulation factor products. Ann Pharmacother 2002; 36:882-891.